ESCC and GC GEJC Treatment | TEVIMBRA® (tislelizumab-jsgr) cancer of the stomach (gastric cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer) TEVIMBRA may be used in combination with chemotherapy that contains platinum and fluoropyrimidine as your first treatment when your gastric or gastroesophageal junction cancer:
Tevimbra Plus Chemo May Be Safe, Effective in Advanced Gastric GEJ Cancer Tevimbra plus POFI demonstrated high efficacy with a 93 5% objective response rate and 100% disease control rate in advanced gastric cancer Median progression-free survival was 10 51 months, and overall survival was 14 75 months, indicating promising outcomes The treatment regimen was well
TEVIMBRA Received FDA Approval as First-Line Therapy for Gastric and . . . The prognosis for patients with gastric or GEJ cancer depends on the stage at diagnosis, treatment response, and overall health Immunotherapies, such as TEVIMBRA (tislelizumab), offer a promising approach for first-line treatment in patients with PD-L1 positive advanced or metastatic gastric and GEJ cancers These newer treatments are vital
FDA Approves Tevimbra Combination for Gastric or Gastroesophageal . . . Tevimbra is a type of precision cancer medicine This humanized IgG4 anti-PD-1 monoclonal antibody was designed specifically to minimize binding to FcγR on macrophages RATIONALE-305 Investigators Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction
FDA Approves Tislelizumab Chemo in Gastric GEJ Adenocarcinoma The FDA previously accepted a biologics license application BLA for tislelizumab plus chemotherapy to treat patients with locally advanced or metastatic gastric or GEJ adenocarcinoma in February 2024 4 References TEVIMBRA approved in U S for first-line treatment of gastric and gastroesophageal junction cancers in combination with chemotherapy
BeiGene’s Tevimbra approved in US for first-line gastric cancer . . . Tevimbra is part of a competitive PD-1 inhibitor market, facing rivals like MSD’s Keytruda (pembrolizumab) and Bristol Myers Squibb’s Opdivo (nivolumab) According to GlobalData’s Pharma Intelligence Center, Tevimbra is set to generate $1 7bn in 2030, whereas Keytruda and Opdivo are forecast to pull in $23 2bn and $9 1bn in sales each
Tevimbra Approved in U. S. for First-line Treatment of Gastric and . . . The additional indication for first-line G GEJ cancers is based on results from BeiGene’s RATIONALE-305 (NCT03777657), a randomized, double-blind, placebo-controlled, global Phase 3 trial to evaluate the efficacy and safety of Tevimbra in combination with chemotherapy as a first-line treatment for adult patients with advanced unresectable or
BeiGene Receives Positive CHMP Opinions for TEVIMBRA “Survival rates in the advanced stages of gastric gastroesophageal and esophageal cancers are among the lowest of all cancer types despite recent advances, and new treatment options are needed
Beigene Tevibra Approved in US for Gastric Cancer Treatment The FDA approved BeiGene's TEVIMBRA (tislelizumab-jsgr), combined with chemotherapy, for first-line treatment of advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma (G GEJ) in adults with PD-L1-positive tumors This approval is based on the positive results from the RATIONALE-305 Phase 3 trial, which showed a significant overall survival benefit for patients receiving